Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

Published Date: 13 May 2024

DFS after three years was 87% after six years as opposed to 55% after three, but the toxicity was higher.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Taking Charge of Your Cancer Journey.

2.

Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam Method

3.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

4.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

5.

Cancer screening rates down among American adults


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot